hepat
c
viru
hcv
remain
import
public
health
threat
approxim
million
carrier
worldwid
risk
develop
hepat
cassoci
endstag
liver
diseas
despit
improv
hcv
treatment
use
novel
directact
antivir
daa
target
viral
replic
lack
prophylact
measur
protect
hcv
infect
identifi
novel
antivir
target
viral
entri
could
help
broaden
therapeut
arsen
hcv
herein
investig
antihcv
activ
methanol
extract
rhizoma
coptidi
rc
wide
use
tradit
chines
medicin
document
experiment
report
possess
sever
pharmacolog
function
includ
antivir
effect
use
cell
culturederiv
hcv
system
demonstr
rc
dosedepend
inhibit
hcv
infect
cell
noncytotox
concentr
particular
rc
block
hcv
attach
entryfus
host
cell
without
exert
signific
effect
cellfre
viral
particl
modul
key
host
cell
entri
factor
hcv
moreov
rc
robustli
suppress
hcv
pseudoparticl
infect
cell
imped
infect
sever
hcv
genotyp
collect
result
identifi
rc
potent
antagonist
hcv
entri
potenti
pangenotyp
properti
deserv
evalu
use
antihcv
agent
virus
sever
notabl
cell
surfac
tight
junction
receptorscoreceptor
includ
heparin
sulfat
proteoglycan
hspg
cluster
differenti
low
densiti
lipoprotein
receptor
ldlr
scaveng
receptor
class
b
type
srbi
occludin
ocln
addit
factor
influenc
viral
entri
includ
apolipoprotein
e
apo
incorpor
infecti
hcv
virion
function
exchang
apolipoprotein
secret
apoeassoci
lipoprotein
hcv
lipoviroparticl
lvp
enhanc
hcv
infect
million
hcv
carrier
worldwid
hcv
infect
lead
chronic
hepat
cirrhosi
liver
cancer
still
effect
vaccin
viru
previou
standard
care
consist
pegylatedinterferon
ifn
combin
ribavirin
associ
sever
import
drawback
includ
sever
side
effect
low
efficaci
hcv
genotyp
recent
introduct
directact
antivir
daa
target
viral
nonstructur
protein
substanti
improv
sustain
virolog
respons
svr
difficult
treat
genotyp
patient
howev
daa
also
challeng
includ
potenti
toxic
especi
drugdrug
interact
ddi
instanc
hcv
proteas
inhibitor
high
risk
ddi
known
substrat
inhibitor
cytochrom
cyp
system
interfer
metabol
drug
includ
immunosuppress
eg
cyclosporin
tacrolimu
coadminist
liver
transplant
set
drugdrug
interact
hcv
daa
includ
acidsuppress
therapi
eg
famotidin
omeprazol
human
immunodefici
viru
hiv
antiretrovir
agent
eg
rilpivirin
efavirenz
shown
decreas
effect
hcv
inhibitor
ledipasvir
produc
advers
drug
reaction
proteas
inhibitor
paritaprevir
respect
addit
due
great
genet
variabl
hcv
select
resist
mutant
becom
challeng
greater
number
peopl
treat
realworld
set
potenti
lead
daa
failur
therefor
continu
identif
novel
candid
drug
particularli
differ
mode
action
improv
current
therapeut
strategi
highli
envisag
rhizoma
coptidi
rc
dri
rhizom
typic
obtain
copti
chinensi
franch
chines
goldthread
medicin
plant
ranunculacea
famili
rc
one
commonli
use
chines
medicin
herb
also
known
huang
lian
document
known
contain
variou
bioactiv
alkaloid
tradit
use
heat
clear
detoxif
effect
treatment
arthriti
burn
eczema
microbi
infect
gastrointestin
diseas
addit
rc
tradit
usag
infect
correl
sever
recent
studi
valid
antimicrobi
function
includ
sever
bacteria
virus
specif
rc
major
constitu
shown
exert
inhibitori
effect
herpesviru
respiratori
syncyti
viru
mous
hepat
viru
infect
preced
suggest
rc
may
potent
sourc
discoveri
novel
antivir
treatment
sinc
effect
rc
hcv
infect
remain
larg
unexplor
attempt
identifi
novel
antihcv
agent
studi
examin
impact
methanol
extract
rc
hcv
infect
result
demonstr
rc
could
robustli
inhibit
hcv
infect
target
earli
step
viral
entri
specif
target
step
includ
viral
attach
entryfus
host
cell
addit
rcmediat
inhibit
hcv
genotypespecif
drug
equal
inhibit
hcv
genotyp
therebi
identifi
rc
potenti
pangenotyp
antihcv
agent
materi
method
cultur
cell
human
hepatoma
cell
deriv
product
cellcultur
deriv
hcv
particl
hcvcc
gaussia
luciferas
reportertag
construct
genotyp
kindli
provid
dr
charl
rice
carri
previous
describ
viru
concentr
express
multipl
infect
moi
hepat
c
viru
hcv
import
liver
pathogen
belong
flavivirida
famili
envelop
posit
singlestrand
rna
genom
hcv
seven
genotyp
genotyp
genom
size
kb
encod
polyprotein
approxim
amino
acid
long
polyprotein
upon
translat
process
viral
host
proteas
yield
matur
protein
includ
structur
protein
core
ion
channel
well
nonstructur
protein
hcv
entri
host
hepatocyt
mediat
interact
basal
media
viral
infect
analys
consist
dulbecco
modifi
eagl
medium
gibcoinvitrogen
carlsbad
ca
usa
contain
fetal
bovin
serum
rhizoma
coptidi
root
copti
chinensi
franch
id
plant
list
obtain
local
pharmaci
store
kaohsiung
taiwan
authent
dr
minghong
yen
use
anatom
method
well
hplc
analysi
comparison
known
molecular
standard
previous
describ
voucher
specimen
deposit
kaohsiung
medic
univers
herbarium
methanol
extract
root
wash
dri
homogen
extract
methanol
follow
concentr
vacuo
methanol
rc
stock
dissolv
dimethyl
sulfoxid
dmso
sigma
st
loui
mo
usa
prior
use
cell
seed
cellswel
plate
overnight
treat
increas
concentr
rc
day
cell
wash
twice
phosphat
buffer
salin
pb
xtt
cell
viabil
analysi
previous
describ
examin
antivir
activ
cell
cellswel
plate
concurr
treat
viru
moi
test
drug
variou
concentr
incub
c
day
antihcv
activ
determin
measur
luciferas
report
signal
use
gaussia
luciferas
assay
kit
new
england
biolab
picker
canada
luminomet
promega
madison
wi
usa
previous
report
data
express
percent
hcv
infect
test
treatment
rel
medium
control
viru
sigma
serv
posit
control
timeofdrugaddit
assay
provid
inform
target
test
agent
viral
life
cycl
consist
pretreat
coaddit
treatment
postinfect
treatment
perform
previous
describ
analys
cell
seed
plate
densiti
cellswel
overnight
infect
hcvcc
carri
moi
luciferas
activ
condit
determin
describ
earlier
follow
h
incub
c
synchron
infect
analysi
determin
effect
test
agent
earli
viral
entri
perform
previous
describ
examin
viral
inactiv
test
drug
incub
cellfre
viru
particl
prior
dilut
virusdrug
mixtur
subtherapeut
concentr
infect
host
cell
final
hcvcc
moi
investig
influenc
viral
attach
prechil
cell
challeng
hcvcc
moi
presenceabs
test
agent
c
allow
bind
viral
particl
host
cell
preclud
entri
test
impact
viral
entryfus
cell
prebound
hcvcc
moi
c
shift
c
incub
presenceabs
test
drug
analys
cell
seed
plate
cellswel
luciferas
activ
condit
determin
describ
earlier
follow
h
incub
c
enzymelink
immunosorb
assay
elisa
base
bind
assay
perform
previous
describ
briefli
prechil
cell
challeng
hcvcc
presenceabs
test
drug
c
h
wash
pb
fix
cell
paraformaldehyd
cellbound
viru
detect
use
primari
antihcv
antibodi
austral
biolog
san
ramon
ca
usa
secondari
goat
antimous
igg
conjug
horseradish
peroxidas
antibodi
invitrogen
follow
assess
tmb
twocompon
microwel
peroxidas
substrat
kit
kpl
gaithersburg
md
usa
absorb
read
nm
micropl
reader
instrument
inc
winooski
vt
usa
retrovir
pseudoparticl
bear
hcv
glycoprotein
produc
follow
previous
describ
method
modif
plasmid
vector
invitrogen
contain
complet
hcv
core
glycoprotein
strain
genotyp
cotransfect
conjunct
pnllucenv
r
construct
envdefect
retrovir
backbon
encod
firefli
luciferas
kindli
provid
dr
cohen
cell
use
transom
technolog
inc
huntsvil
al
usa
supernat
contain
viral
pseudoparticl
harvest
filter
concentr
use
vv
polyethylen
glycol
store
c
use
infect
experi
hcv
pseudoparticl
hcvpp
use
inocul
cell
monolay
plate
presenc
absenc
test
agent
h
c
cell
wash
pb
incub
basal
media
h
harvest
assess
report
luciferas
activ
use
firefli
luciferas
assay
kit
promega
luminomet
viral
infect
calcul
percent
rel
light
unit
rlu
compar
control
viru
antivir
activ
recombin
hcv
carri
glycoprotein
genotyp
virus
kindli
provid
dr
jen
bukh
perform
use
previous
report
method
modif
cell
cellswel
plate
challeng
virus
moi
presenceabs
test
agent
day
incub
detect
viral
infect
perform
immunofluoresc
stain
hcv
foci
use
primari
mous
anticor
clone
antibodi
anogen
mississauga
canada
crossreact
differ
hcv
core
antigen
determin
secondari
alexa
fluor
goat
antimous
igg
hl
invitrogen
hcvposit
foci
quantit
result
plot
dmso
control
statist
analysi
conduct
use
oneway
analysi
varianc
anova
follow
tukey
multipl
comparison
test
unpair
test
p
valu
less
p
consid
statist
signific
data
express
mean
standard
error
mean
sem
three
independ
experi
given
numer
pharmacolog
properti
rc
hypothes
medicin
herb
could
potenti
possess
antivir
activ
hcv
explor
possibl
cell
infect
gaussia
luciferas
reportertag
hcvcc
presenc
differ
concentr
methanol
extract
rc
luciferas
activ
subsequ
assess
determin
viral
infect
cytotox
assay
simultan
perform
cell
drug
concentr
result
show
rc
could
inhibit
hcv
infect
dosedepend
without
induc
signific
cytotox
figur
cytotox
concentr
cc
effect
concentr
ec
select
index
si
cc
ec
determin
respect
figur
sinc
antivir
efficaci
rc
appear
compar
concentr
chosen
remaind
experi
given
numer
pharmacolog
properti
rc
hypothes
medicin
herb
could
potenti
possess
antivir
activ
hcv
explor
possibl
cell
infect
gaussia
luciferas
reportertag
hcvcc
presenc
differ
concentr
methanol
extract
rc
luciferas
activ
subsequ
assess
determin
viral
infect
cytotox
assay
simultan
perform
cell
drug
concentr
result
show
rc
could
inhibit
hcv
infect
dosedepend
without
induc
signific
cytotox
figur
cytotox
concentr
effect
concentr
select
index
si
determin
respect
figur
sinc
antivir
efficaci
rc
appear
compar
concentr
chosen
remaind
experi
order
narrow
window
antivir
activ
rc
perform
timeofdrugaddit
assay
wherein
drug
either
ad
cell
h
hcvcc
infect
pretreat
concurr
ad
time
viral
infect
coaddit
ad
infect
postinfect
incub
day
measur
luciferas
report
activ
result
indic
signific
differ
hcv
infect
presenc
absenc
rc
pretreat
figur
suggest
drug
appear
modul
host
cell
hcv
infect
contrast
rc
significantli
inhibit
hcv
infect
simultan
ad
viral
challeng
indic
substanti
drop
luciferas
signal
figur
moder
decreas
viral
infect
observ
drug
ad
establish
viral
infect
contrast
serv
posit
control
effect
inhibit
hcvcc
infect
type
treatment
thu
rc
antihcv
activ
appear
order
narrow
window
antivir
activ
rc
perform
timeofdrugaddit
assay
wherein
drug
either
ad
cell
h
hcvcc
infect
pretreat
concurr
ad
time
viral
infect
coaddit
ad
infect
postinfect
incub
day
measur
luciferas
report
activ
result
indic
signific
differ
hcv
infect
presenc
absenc
rc
pretreat
figur
suggest
drug
appear
modul
host
cell
hcv
infect
contrast
rc
significantli
inhibit
hcv
infect
simultan
ad
viral
challeng
indic
substanti
drop
luciferas
signal
figur
moder
decreas
viral
infect
observ
drug
ad
establish
viral
infect
contrast
serv
posit
control
effect
inhibit
hcvcc
infect
type
treatment
thu
rc
antihcv
activ
appear
strongest
concurr
present
host
cell
viral
particl
suggest
inhibitori
effect
mainli
target
earli
phase
hcv
infect
includ
viral
entri
virus
x
peer
review
strongest
concurr
present
host
cell
viral
particl
suggest
inhibitori
effect
mainli
target
earli
phase
hcv
infect
includ
viral
entri
character
mechan
underli
rc
antihcv
effect
strongest
rc
simultan
present
viru
host
cell
surfac
perform
synchron
infect
assay
earli
viral
entri
test
whether
rc
could
inactiv
cellfre
viral
particl
drug
preincub
hcvcc
h
dilut
infect
cell
drugviru
mixtur
dilut
yield
noneffect
concentr
subsequ
ad
cell
incub
day
luciferas
read
follow
day
incub
show
signific
differ
sampl
treat
without
rc
suggest
drug
impact
free
viral
particl
figur
determin
effect
rc
viral
attach
specif
ad
rc
hcv
cell
bind
allow
viru
bind
preclud
viral
intern
test
report
readout
end
incub
result
demonstr
signific
decreas
luciferas
report
activ
indic
rc
interf
attach
viru
host
cell
figur
ascertain
whether
rc
influenc
postattach
viral
entryfus
step
cell
prebound
hcv
shift
temperatur
presenc
rc
similar
effect
observ
viral
attach
data
reveal
signific
decreas
hcv
infect
end
incub
suggest
rc
equal
block
hcv
entryfus
figur
character
mechan
underli
rc
antihcv
effect
strongest
rc
simultan
present
viru
host
cell
surfac
perform
synchron
infect
assay
earli
viral
entri
test
whether
rc
could
inactiv
cellfre
viral
particl
drug
preincub
hcvcc
h
dilut
infect
cell
drugviru
mixtur
dilut
yield
noneffect
concentr
subsequ
ad
cell
incub
day
luciferas
read
follow
day
incub
show
signific
differ
sampl
treat
without
rc
suggest
drug
impact
free
viral
particl
figur
determin
effect
rc
viral
attach
specif
ad
rc
hcv
cell
bind
c
allow
viru
bind
preclud
viral
intern
test
report
readout
end
incub
result
demonstr
signific
decreas
luciferas
report
activ
indic
rc
interf
attach
viru
host
cell
figur
ascertain
whether
rc
influenc
postattach
viral
entryfus
step
cell
prebound
hcv
c
shift
temperatur
c
presenc
rc
similar
effect
observ
viral
attach
data
reveal
signific
decreas
hcv
infect
end
incub
suggest
rc
equal
block
hcv
entryfus
figur
directli
valid
find
rc
inhibit
hcv
attach
host
cell
employ
elisabas
bind
assay
cell
inocul
hcvcc
presenc
rc
c
h
cell
wash
fix
subject
colorimetr
analysi
detect
cell
surfacebound
hcv
particl
use
antihcv
antibodi
depict
figur
rc
treatment
dosedepend
decreas
viral
attach
demonstr
sharp
declin
absorb
signal
agreement
result
hcv
entri
step
mediat
viral
glycoprotein
base
inhibitori
effect
observ
rc
hcv
entri
step
valid
antivir
potenc
hcv
entri
examin
impact
rc
treatment
infect
retrovir
pseudoparticl
bear
hcv
glycoprotein
hcvpp
specif
luciferasetag
hcvpp
use
infect
cell
presenc
absenc
rc
incub
cell
assess
luciferas
report
activ
readout
viral
infect
demonstr
figur
rc
robustli
suppress
hcvpp
infect
hepatoma
cell
compar
dmso
control
result
therefor
confirm
valid
antivir
capac
rc
viral
entri
stage
hcv
hcv
infect
hepatocyt
wellorchestr
process
involv
engag
sever
host
factor
includ
srbi
ocln
addit
apo
also
report
play
role
mediat
hcv
entri
given
rc
treatment
block
hcv
infect
mainli
target
viral
entri
next
ask
whether
drug
could
modul
express
key
host
cell
entri
factor
end
cell
pretreat
rc
h
harvest
cell
lysat
western
blot
analysi
depict
figur
pretreat
cell
rc
alter
express
srbi
ocln
similarli
express
apo
affect
rc
treatment
figur
apob
particip
hcv
virion
releas
includ
comparison
neither
affect
drug
treatment
result
therefor
suggest
rc
inhibit
hcv
infect
via
influenc
host
cell
consist
data
pretreat
analysi
figur
sinc
rc
appear
primarili
target
hcv
entri
final
sought
examin
whether
medicin
herb
also
possess
pangenotyp
activ
hcv
purpos
cell
seed
infect
recombin
hcvcc
express
glycoprotein
genotyp
presenc
rc
incub
analysi
hcv
infect
immunofluoresc
stain
result
show
signific
decreas
viral
infect
across
test
hcv
genotyp
rc
present
suggest
may
possess
pangenotyp
activ
hcv
figur
continu
identif
novel
antivir
variou
mode
action
import
given
develop
drug
resist
commonplac
especi
virus
exhibit
genet
variabl
includ
hcv
studi
demonstr
first
time
methanol
extract
rc
robustli
inhibit
hcv
infect
specif
rc
mainli
target
hcv
earli
viral
entri
step
attach
entryfus
host
cell
interestingli
rc
also
inhibit
hcv
infect
sever
genotyp
result
therefor
identifi
rc
promis
antagonist
pangenotyp
function
hcv
entri
could
use
develop
hcv
prophylaxi
current
approv
therapeut
treatment
exist
target
hcv
entri
patient
chronic
hepat
c
risk
endstag
liver
diseas
cirrhosi
liver
cancer
necessit
liver
transplant
importantli
donor
liver
inadvert
becom
reinfect
almost
immedi
transplant
hepat
c
patient
given
daa
current
use
prevent
liver
graft
reinfect
propens
select
drugresist
mutant
combin
entri
inhibitor
daa
would
expect
broaden
treatment
strategi
hepat
c
especi
liver
transplant
set
interestingli
previou
studi
demonstr
combin
daa
viru
entri
inhibitor
produc
synergist
effect
improv
drug
efficaci
discoveri
rc
antagon
hcv
entri
make
ideal
candid
use
liver
transplant
scenario
test
combin
daa
better
therapeut
efficaci
natur
resourc
plant
materi
serv
excel
start
point
antivir
discoveri
rc
antihcv
bioactiv
identifi
medicin
herb
import
antivir
sourc
treatment
hepat
c
variou
medicin
plant
extract
shown
possess
antihcv
properti
thereaft
serv
sourc
identifi
small
molecul
inhibitor
exampl
specif
target
hcv
entri
includ
silibinin
silymarin
silybum
marianum
gallic
acid
found
limonium
sinens
loliolid
butenolid
deriv
phyllanthu
urinaria
ladanein
isol
marrubium
peregrinum
l
lamiacea
bupleurum
kaoi
terpenoid
saikosaponin
molecular
constitu
rc
contribut
antihcv
activ
remain
identifi
alkaloid
potenti
candid
bioactiv
known
major
compon
rc
typic
present
alcohol
extract
herb
exampl
includ
berberin
coptisin
palmatin
epiberberin
columbamin
jatrorrhizin
groenlandicin
among
major
compound
whether
singl
compound
combin
contribut
rc
antivir
action
hcv
remain
explor
indepth
analysi
would
requir
fulli
elucid
bioactiv
ingredi
respons
rc
antihcv
effect
result
indic
rc
specif
block
hcv
attach
entryfus
host
cell
without
significantli
influenc
cellfre
viral
particl
modul
key
host
cell
continu
identif
novel
antivir
variou
mode
action
import
given
develop
drug
resist
commonplac
especi
virus
exhibit
genet
variabl
includ
hcv
studi
demonstr
first
time
methanol
extract
rc
robustli
inhibit
hcv
infect
specif
rc
mainli
target
hcv
earli
viral
entri
step
attach
entryfus
host
cell
interestingli
rc
also
inhibit
hcv
infect
sever
genotyp
result
therefor
identifi
rc
promis
antagonist
pangenotyp
function
hcv
entri
could
use
develop
hcv
prophylaxi
current
approv
therapeut
treatment
exist
target
hcv
entri
patient
chronic
hepat
c
risk
endstag
liver
diseas
cirrhosi
liver
cancer
necessit
liver
transplant
importantli
donor
liver
inadvert
becom
reinfect
almost
immedi
transplant
hepat
c
patient
given
daa
current
use
prevent
liver
graft
reinfect
propens
select
drugresist
mutant
combin
entri
inhibitor
daa
would
expect
broaden
treatment
strategi
hepat
c
especi
liver
transplant
set
interestingli
previou
studi
demonstr
combin
daa
viru
entri
inhibitor
produc
synergist
effect
improv
drug
efficaci
discoveri
rc
antagon
hcv
entri
make
ideal
candid
use
liver
transplant
scenario
test
combin
daa
better
therapeut
efficaci
natur
resourc
plant
materi
serv
excel
start
point
antivir
discoveri
rc
antihcv
bioactiv
identifi
medicin
herb
import
antivir
sourc
treatment
hepat
c
variou
medicin
plant
extract
shown
possess
antihcv
properti
thereaft
serv
sourc
identifi
small
molecul
inhibitor
exampl
specif
target
hcv
entri
includ
silibinin
silymarin
silybum
marianum
gallic
acid
found
limonium
sinens
loliolid
butenolid
deriv
phyllanthu
urinaria
ladanein
isol
marrubium
peregrinum
l
lamiacea
bupleurum
kaoi
terpenoid
saikosaponin
molecular
constitu
rc
contribut
antihcv
activ
remain
identifi
alkaloid
potenti
candid
bioactiv
known
major
compon
rc
typic
present
alcohol
extract
herb
exampl
includ
berberin
coptisin
palmatin
epiberberin
columbamin
jatrorrhizin
groenlandicin
among
major
compound
whether
singl
compound
combin
contribut
rc
antivir
action
hcv
remain
explor
indepth
analysi
would
requir
fulli
elucid
bioactiv
ingredi
respons
rc
antihcv
effect
result
indic
rc
specif
block
hcv
attach
entryfus
host
cell
without
significantli
influenc
cellfre
viral
particl
modul
key
host
cell
entri
factor
hcv
abil
rc
inhibit
hcvpp
infect
suggest
mechanist
target
may
involv
hcv
glycoproteinsmedi
interact
host
cell
potenti
mechan
transient
interact
hcv
glycoprotein
inadequ
inactiv
free
viral
particl
suffici
effect
hinder
contact
cell
surfac
receptorscoreceptor
addit
mechan
action
could
also
includ
concentrationdepend
revers
conform
alter
receptorscoreceptor
viral
particl
structur
block
viral
entri
also
note
moder
effect
rc
postinfect
stage
figur
albeit
less
pronounc
compar
impact
inhibit
hcv
entri
step
effect
entir
due
inhibit
entri
subsequ
de
novo
infect
cycl
sinc
treatment
subgenom
hcv
replicon
cell
rc
also
show
moder
decreas
viral
rna
preliminari
experi
figur
possibl
rc
may
possess
multipl
mechan
hcv
infect
would
necessit
studi
clarif
nonetheless
result
clearli
demonstr
rc
potent
inhibit
hcv
entri
therefor
suggest
rc
could
explor
prophylactictherapeut
manag
hepat
c
supplementari
materi
follow
avail
onlin
http
figur
effect
rc
treatment
hcv
subgenom
replicon
cell
